Lenvatinib Mesylate CAS 857890-39-2 Assay 98.0 ~ 102.0% Ụlọ ọrụ

Lenvatinib Mesylate (CAS: 857890-39-2) bụ onye na-egbochi ọnụ na ọtụtụ ezubere iche nke VEGFR1-3, FGFR1-4, PDGFR, KIT, na RET, nwere ọrụ mgbochi mgbochi.Lenvatinib Mesylate bụ onye na-anabata tyrosine kinase (RTK) inhibitor nke nwere nhọrọ maka VEGFR2.Ọ na-egosipụta ọrụ antineoplastic, ma egosiwo ya maka ọgwụgwọ nke ndị ọrịa na-emeghachi omume na mpaghara ma ọ bụ metastatic, na-aga n'ihu, radioactive iodine (RAI) -refractory differentiated thyroid cancer.Lenvatinib Mesylate bụ nke US Food and Drug Administration (FDA) kwadoro nke mbụ na Febrụwarị 13, 2015, wee kwado ya site na Pharmaceuticals and Medical Devices Agency of Japan (PMDA) na Mar 26, 2015, ma kwadoro ya na European Medicine Agency (EMA) na Ọnwa Ise 28, 2015. Emepụtara ya wee zụọ ahịa dị ka Lenvima® site n'aka Eisai.Lenvatinib Mesylate bụ onye na-anabata ọnụ tyrosine kinase inhibitor nwere ụdị njigide pụrụ iche nke na-ahọrọ nke na-egbochi ọrụ kinase nke ndị na-anabata vaskụla endothelial (VEGF), na mgbakwunye na proangiogenic na oncogenic ụzọ metụtara tyrosine kinases chere na ha na-etinye aka na mmụba tumor. .A na-egosi ya maka ọgwụgwọ ọrịa cancer thyroid na-aga n'ihu na redioiodine-refractory.LenvimaA na-eji ya n'onwe ya na-agwọ ọrịa cancer thyroid dị iche iche (DTC), ụdị ọrịa cancer thyroid nke a na-apụghịzi agwọ ya na iodine redioaktivu ma na-aga n'ihu.A na-eji LENVIMA na ọgwụ ọzọ a na-akpọ everolimus agwọ ndị toro eto nwere ụdị ọrịa kansa akụrụ nke a na-akpọ Advanced Renal cell carcinoma (RCC) ka e werechara ọgwụ ọzọ na-egbochi ọrịa kansa gwọọ ya.